FDA panel to weigh Myozyme expansion

The FDA questions whether a study submitted by Genzyme is strong enough to merit expanded approval of a drug to treat a rare illness known as Pompe disease; the drug, Myozyme, is up for advisory committee discussion tomorrow. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.